Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 8

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 8
---
 include: (i) multi-omics integration for target identification and validation; (ii) predictive modeling of
therapeutic efficacy and safety; (iii) clinical trial optimization, including patient stratification and response monitoring; and (iv)
experimental screening of gene and small molecule effects for the purpose of identifying novel drug targets and therapeutics.

The key to the BioSymetrics approach is Contingent
AI. In Contingent AI, any “settable” parameter for data processing, data integration, or feature selection is permuted and
the corresponding effects on the downstream predictive model measured. This process is similar in nature to hyperparameter tuning in machine
learning, however instead of optimizing only the machine learning model, the entire data science pipeline (including model selection)
is subject to optimization. We have applied this method extensively in drug discovery, producing marked improvements in experiment interpretation
and lead generation.

Recent Developments

Name Change

On August 18, 2025, the Company
filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to
change its corporate name from “Renovaro Inc.” to “Lunai Bioworks Inc.” (the “Name Change”). The Name
Change became effective on August 20, 2025. The Company changed its name to signify its focus on the development and validation of its
AI-driven cancer diagnostics platform.

Exchange of Secured Promissory Notes

On July 7, 2025, the Company entered
into an Exchange Agreement (the “Exchange Agreement”) with certain accredited investors (the “Investors”), all
of whom were existing shareholders of the Company. Pursuant to the Exchange Agreement, the Investors agreed to exchange an aggregate of
$9.7 million in outstanding secured promissory notes (the “Secured Notes”) for $16.1 million in new convertible promissory
notes (the “Convertible Notes”), representing a 65% premium to the principal and interest amount of the Secured Notes. The
Convertible Notes had a maturity date of July 31, 2025 and did not bear any interest. The exchange was completed to restructure the Company’s
debt obligations and provide additional flexibility to support strategic initiatives.

Immediately following the issuance
of the Convertible Notes on July 7, 2025, the Investors elected to convert the entire $16.1 million principle amount into an aggregate
of 53.6 million shares of common stock (the “